Epalrestat Capsules
Function and Efficacy
Pharmacological action: Epalrestat is a reversible non-competitive inhibitor of aldose reductase, which has a selective inhibitory effect on aldose reductase. Clinical studies have shown that epalrestat can inhibit the accumulation of sorbitol in the erythrocytes of patients with diabetic peripheral neuropathy, and can improve the patients' subjective symptoms and neurological dysfunction compared with the control group. Animal experiments have shown that epalrestat can significantly inhibit the accumulation of sorbitol in the sciatic nerve, erythrocytes, and retina of diabetic model rats, and improve their motor nerve conduction velocity and autonomic nerve function; in terms of neuromorphology, epalrestat can improve axonal flow abnormalities, increase the density of myelinated nerve fibers in the sciatic nerve, the thickness of the myelin sheath of the sural nerve, the axon area, and the axon cylindricality; in addition, epalrestat can also improve the model's motor
Ingredients
5-[(1Z, 2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| EpalrestatIngredients |
Epalrestat is a reversible non-competitive inhibitor of aldose reductase, which has a selective inhibitory effect on aldose reductase. Clinical studies have shown that epalrestat can inhibit the accumulation of sorbitol in erythrocytes of patients with diabetic peripheral neuropathy, and can improve patients' subjective symptoms and neurological dysfunction compared with the control group. Animal experiments have shown that epalrestat can significantly inhibit the accumulation of sorbitol in the sciatic nerve, erythrocytes, and retina of diabetic model rats, and improve their motor nerve conduction velocity and autonomic nerve function; in terms of nerve morphology, epalrestat can improve axonal flow abnormalities, increase the density of myelinated nerve fibers in the sciatic nerve, the thickness of the myelin sheath of the sural nerve, the axon area, and the axon cylindrical rate. More |
82159-09-9 | 18 |
Appearance
This product is a hard capsule, and the contents are orange-red powder.
Indication
Diabetic neuropathy.
Usage and Dosage
The usual adult dose is 50 mg (1 tablet) three times a day, taken orally before meals.
Adverse Reactions
1. Allergy: Occasionally erythema, blisters, rash, itching. 2. Liver: Occasionally elevated bilirubin, AST, ALT, r-GTP, jaundice. 3. Digestive system: Occasionally diarrhea, nausea, vomiting, abdominal pain, loss of appetite, abdominal distension, stomach discomfort. Kidney: Occasionally elevated creatinine. 5. Blood system: decreased platelets. 6. Others: Very rarely dizziness, vertigo, neck pain, fatigue, drowsiness, edema, limb pain, numbness, hair loss.
Precautions
It is contraindicated for those who are allergic to this product.
Special Population Medication
Precautions for children: There is no experience of safety of this product for children. Precautions for pregnancy and lactation: There is currently no safety data for this product in pregnant women. Therefore, pregnant women should be extremely cautious when using this product and weigh the pros and cons before deciding whether to use it. Animal experiments have shown that this product can be excreted through breast milk. Therefore, breastfeeding women should avoid using this product. Precautions for the elderly: Elderly patients should consider appropriate reductions when using this product due to changes in physiological functions.
Drug Interactions
Not yet clear
Storage
Store in a sealed container in a dark place. 24 months
Packaging Specification
50mg
Validity Period
24 months
Manufacturer
YANGTZE River Pharmaceutical Group Nanjing Pharmaceutical. Co., Ltd.
-
Founded in:
2001-01-16 -
Address:
No. 9 Xianlin Avenue, Qixia District, Nanjing -
Tax NO.:
91320192726063334T -
Registered Funds:
50 million yuan -
Website:
-
Email: